At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Tirabrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Tirabrutinib, Entospletinib, and 1 other intervention for Chronic Lymphocytic Leukemia. Completed, enrolled 36 participants across 15 sites.
Detailed Summary
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesGermany
CollaboratorsGerman CLL Study Group
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartApr 2017
Primary CompletionFeb 2019
Study CompletionOct 2020
TodayJul 2026
First PostedDec 6, 2016
Enrollment StartApr 6, 2017
Primary CompletionFeb 20, 2019
Study CompletionOct 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.6 years ago
Interventions
Tirabrutinibdrug
Administered orally once daily
Entospletinibdrug
Administered orally once daily
Obinutuzumabdrug
Administered intravenously